Advertisement

Human Physiology

, Volume 44, Issue 8, pp 896–900 | Cite as

Prevention of Cerebrovascular Disease in Patients with Myeloproliferatie Disorders

  • M. M. Tanashyan
  • P. I. Kuznetsova
  • A. A. Shabalina
  • A. A. RaskurazhevEmail author
Article

Abstract

Introduction. Hemorheological abnormalities in patients with Ph-negative myeloproliferative disorders (MPD) may lead to the development and/or progression of cerebrovascular pathology. Adequate preventive therapy in such cases lowers the risk of cerebral thrombotic complications. Objective. Evaluation of the effect of dipyridamole and acetylsalicylic acid (ASA) on platelet and erythrocyte aggregation, as well as on morphofunctional properties of erythrocytes in patients with cerebrovascular disease (CVD) due to MPD. Materials and methods. The study comprised 40 patients with various forms of CVD and Рh-negative MPD: 20 patients received dipyridamole, and 20 received ASA for prevention of cerebral thrombotic complications. Mean patient’s age was 44.6 years [35; 58.5]. A thorough clinical and neurological examination was performed, as well as neuroimaging studies, coagulation tests, analysis of platelet aggregation and rheological properties of erythrocytes. Results. Within the observation period (median—6.3 months) no acute cerebrovascular events in both groups were registered. Platelet aggregation (induced by ADP or adrenaline) was similar in both groups. Dipyridamole and ASA were also similar in their effect on functional properties of erythrocytes. Conclusion. Our findings suggest that the therapeutic effect of dipyridamole concerning CVD is similar to that of ASA. Dipyridamole can be recommended for use in patients with Рh-negative MPD if other antiplatelet agents are contraindicated.

Keywords:

cerebrovascular pathology myeloproliferative disorders dipyridamole acetylsalicylic acid endothelial function platelet and erythrocyte aggregation erythrocyte deformability 

REFERENCES

  1. 1.
    Duangnapasatit, B., Rattarittamrong, E., Rattanathammethee, T., et al., Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms, Asian Pac. J. Cancer Prev., 2015, vol. 16, no. 12, pp. 5013–5018. PMID 26163633. doi 10.7314/APJCP.2015.16.12.5013CrossRefGoogle Scholar
  2. 2.
    Tefferi, A., Thiele, J., and Vardiman, J.W., The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos, Cancer, 2009, vol. 115, no. 9, pp. 3842–3847. PMID 19472396. doi 10.1002/cncr.24440CrossRefGoogle Scholar
  3. 3.
    Tefferi, A., Pathogenesis of myelofibrosis with myeloid metaplasia, J. Clin. Oncol., 2005, vol. 23, no. 33, pp. 8520–8530. PMID 16293880. doi 10.1200/JCO. 2004.00.9316CrossRefGoogle Scholar
  4. 4.
    Alvarez-Larrán, A., Cervantes, F., Bellosillo, B., et al., Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients, Leukemia, 2007, vol. 21, no. 6, pp. 1218–1223. PMID 17519959. doi 10.1038/sj.leu.2404693CrossRefGoogle Scholar
  5. 5.
    Kaifie, A., Kirschner, M., Wolf, D., et al., Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J. Hematol. Oncol., 2016, vol. 9, p. 18. doi 10.1186/ s13045-016-0242-9CrossRefGoogle Scholar
  6. 6.
    Arellano-Rodrigo, E., Alvarez-Larrán, A., Rever-ter, J.C., et al., Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status, Haematologica, 2006, vol. 91, no. 2, pp. 169–175. PMID 16461300Google Scholar
  7. 7.
    Falanga, A., Marchetti, M., Vignoli, A., et al., V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules, Exp. Hematol., 2007, vol. 35, no. 5, pp. 702–711. PMID 17577920CrossRefGoogle Scholar
  8. 8.
    Falanga, A., Marchetti, M., Barbui, T., and Smith, C.W., Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils, Semin. Hematol., 2005, vol. 42, no. 4, pp. 239–247. doi 10.1053/j.seminhematol.2005.05.023CrossRefGoogle Scholar
  9. 9.
    Marchetti, M. and Falanga, A., Leukocytosis, JAK2V617F mutation, and homeostasis in myeloproliferative disorders, Pathophysiol. Haemostasis Thromb., 2008, vol. 36, nos. 3–4, pp. 148–159. PMID 19176988. doi 10.1159/000175153CrossRefGoogle Scholar
  10. 10.
    Falanga, A., Marchetti, M., Vignoli, A., et al., Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera, Exp. Hematol., 2005, vol. 33, no. 5, pp. 523–530. PMID 15850829. doi 10.1016/j.exphem.2005.01.015CrossRefGoogle Scholar
  11. 11.
    De Stefano, V., Za, T., Rossi, E., et al., Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia, Haematologica, 2009, vol. 94, no. 5, pp. 733–737. PMID 19336736. doi 10.3324/haematol.13869CrossRefGoogle Scholar
  12. 12.
    Campbell, P.J., MacLean, C., Beer, P.A., et al., Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort, Blood, 2012, vol. 120, no. 7, pp. 1409–1411. doi 10.1182/ blood-2012-04-424911CrossRefGoogle Scholar
  13. 13.
    Derry, S. and Loke, Y.K., Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis, Br. Med. J., 2000, vol. 321, no. 7270, pp. 1183–1187. https://doi.org/10.1136/bmj.321.7270.1183.CrossRefGoogle Scholar
  14. 14.
    Tanashyan, M., Kuznetsova, P., Shabalina, A., et al., Clinical characteristics of cerebrovascular pathology with patients suffering from Ph-negative myeloproliferative disease, Cerebrovasc. Dis. Extra, 2016, vol. 6, no. 3, pp. 66–70. PMID 27598581. doi 10.1159/000448597CrossRefGoogle Scholar
  15. 15.
    Kim, H.H. and Liao, J.K., Translational therapeutics of dipyridamole, Arterioscler., Thromb., Vasc. Biol., 2008, vol. 28, pp. 39–42. PMID 18174451. doi 10.1161/ATVBAHA.107.160226CrossRefGoogle Scholar
  16. 16.
    Leonardi-Bee, J., Bath, P.M., Bousser, M.G., et al., Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials, Stroke, 2005, vol. 36, no. 1, pp. 162–168. doi 10.1161/01.STR.0000149621.95215.eaCrossRefGoogle Scholar
  17. 17.
    Tanashyan, M.M. and Domashenko, M.A., Dipiridamol in the complex therapy of chronic cerebrovascular disease, Nervnye Bolezni, 2012, no. 3, pp. 27–30.Google Scholar
  18. 18.
    Michiels, J.J., Koudstaal, P.J., and Mulder, A.H., Transient neurologic and ocular manifestations in primary thrombocythemia, Neurology, 1993, vol. 43, pp. 1107–1110. PMID 8170552CrossRefGoogle Scholar
  19. 19.
    Lengfelder, E., Hochhaus, A., Kronawitter, U., et al., Should a platelet limit of 600 × 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages, Br. J. Haematol., 1998, vol. 100, pp. 15–23. PMID 9450785CrossRefGoogle Scholar
  20. 20.
    Michiels, J.J., Berneman, Z., and Schroyens, W., Plateled-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia, Platelets, 2006, vol. 17, pp. 528–544. PMID 17127481. doi 10.1080/09537100600758677CrossRefGoogle Scholar
  21. 21.
    Harrison, C., Pregnancy and its management in the Philadelphia negative myeloproliferative diseases, Br. J. Haematol., 2005, vol. 129, pp. 293–306. PMID 15842653. doi 10.1111/j.1365-2141.2005.05400.xCrossRefGoogle Scholar
  22. 22.
    Tanashyan, M.M., Kuznetsova, P.I., Lagoda, O.V., et al., Myeloproliferative diseases and ischemic stroke, Ann. Klin. Eksp. Nevrol., 2014, vol. 8, no. 2, pp. 41–45.Google Scholar
  23. 23.
    Tanashyan, M.M. and Domashenko, M.A., Kurantil use for patients with chronic cerebrovascular disease, Nervnye Bolezni, 2005, no. 3, pp. 8–11.Google Scholar

Copyright information

© Pleiades Publishing, Inc. 2018

Authors and Affiliations

  • M. M. Tanashyan
    • 1
  • P. I. Kuznetsova
    • 1
  • A. A. Shabalina
    • 1
  • A. A. Raskurazhev
    • 1
    Email author
  1. 1.Research Center of NeurologyMoscowRussia

Personalised recommendations